Eli Lilly and CompanyLLYNYSE
Loading
A large-scale business, with exceptional profitability, showing strong growth priced at a premium.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.
Comprehensive financial statement data for deep analysis
| Metric | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 74.2% | 76.8%↑3.5% | 79.2%↑3.2% | 81.3%↑2.6% | 83.8%↑3.1% |
| Operating Margin | 28.0% | 30.3%↑8.2% | 31.6%↑4.3% | 38.9%↑22.9% | 45.6%↑17.3% |
| Net Margin | 19.7% | 21.9%↑11.0% | 15.4%↓29.8% | 23.5%↑53.1% | 31.7%↑34.7% |
| Earnings Yield | - | - | - | - | - |